8-K filing — GT Biopharma, Inc. (GTBP)
Filed: 2026-06-12 AccNo: 0001493152-26-028457 Size: 221 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
GT Biopharma Q2 EPS $(0.12) Misses $(0.08) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.08) by 50 percent. This is a 78.18 percent increase over losses of $(0.55) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 12:29 PM
- Checked
- Aug 14, 2026, 12:29 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
GT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.
Read original at benzingaEXCLUSIVE: GT Biopharma Implements AI Initiatives To Accelerate Pipeline Discovery, Reduce Costs, Explores Opportunities Beyond Oncology
Read original at benzinga